Table 1

Patient and tumor characteristics (n = 108)
n/estimation %
Age (years)
 Mean ± standard deviation 58.4 ± 10.2
 Median (range) 59 (29–78)
ECOG performance status on chemotherapy day 1
 0 42 39
 1 57 53
 2 8 7
HER2 overexpression
2+/FISH + 8 7
3+ 97 90
FISH +/no immunohistochemistry or other 3 3
Tumor grade (n = 102)
 G1 2 2
 G2 47 46
 G3 53 52
Metastatic sites at onset of study treatment (n)
 Mean ± standard deviation 1.8 ± 0.9
 Median, range 2 (1–5)
Organ site involvement
 Local/skin 14 13
 Lymph nodes, non-regional 20 19
 Bone 41 38
 Liver 48 44
 Lung 49 45
 Pleural effusion 13 12
 Genitourinary 1 1
 Other 9 8
Previous treatment
 Neoadjuvant chemotherapy 11 10
 Adjuvant chemotherapy 74 69
 Adjuvant endocrine therapy 45 42
 Palliative chemotherapy 40 37
 Palliative endocrine therapy 34 31

Abbreviations

ECOG: Eastern Cooperative Oncology Group.

FISH: fluorescence in-situ hybridization.

John et al.

John et al. BMC Cancer 2012 12:165   doi:10.1186/1471-2407-12-165

Open Data